ATE361059T1 - Antivirale zusammensetzungen - Google Patents

Antivirale zusammensetzungen

Info

Publication number
ATE361059T1
ATE361059T1 AT03768857T AT03768857T ATE361059T1 AT E361059 T1 ATE361059 T1 AT E361059T1 AT 03768857 T AT03768857 T AT 03768857T AT 03768857 T AT03768857 T AT 03768857T AT E361059 T1 ATE361059 T1 AT E361059T1
Authority
AT
Austria
Prior art keywords
antiviral compositions
antiviral
compositions
oxathiolan
deoxythymidine
Prior art date
Application number
AT03768857T
Other languages
English (en)
Inventor
Gary Wayne Goodson
Alison Green Floyd
Cecilia Carpenter Navy
Original Assignee
Glaxo Group Ltd
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Smithkline Beecham Corp filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE361059T1 publication Critical patent/ATE361059T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03768857T 2002-11-08 2003-11-07 Antivirale zusammensetzungen ATE361059T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42518202P 2002-11-08 2002-11-08

Publications (1)

Publication Number Publication Date
ATE361059T1 true ATE361059T1 (de) 2007-05-15

Family

ID=32312939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03768857T ATE361059T1 (de) 2002-11-08 2003-11-07 Antivirale zusammensetzungen

Country Status (9)

Country Link
US (1) US20050287177A1 (de)
EP (1) EP1567133B1 (de)
JP (1) JP2006508134A (de)
AT (1) ATE361059T1 (de)
AU (1) AU2003291457A1 (de)
CA (1) CA2505130C (de)
DE (1) DE60313657T2 (de)
ES (1) ES2286471T3 (de)
WO (1) WO2004043433A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE602004019541D1 (de) 2003-08-26 2009-04-02 Smithkline Beecham Corp Cycloalkyläbü kondensierte indole
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
BRPI0620705A2 (pt) * 2005-12-14 2011-11-22 Cipla Ltd formulação farmacêutica em uma forma única de dosagem unitária, produto farmacêutico, uso de uma formulação farmacêutico e uso de um inibidor de transcriptase-reversa de nucleosìdeo ou derivado fisiologicamente funcional do mesmo e um inibidor de transcriptase-reversa de nucleotìdeo ou derivado fisiologicamente funcional do mesmo
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP2010529073A (ja) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
AU2008258627A1 (en) * 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
JP2010530890A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
KR101057640B1 (ko) * 2009-05-27 2011-08-18 (주)다산메디켐 발포성 층을 포함하는 다층 정제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US6177435B1 (en) * 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
DE69327004T2 (de) * 1992-08-04 2000-06-29 James M Dunn Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof

Also Published As

Publication number Publication date
ES2286471T3 (es) 2007-12-01
CA2505130C (en) 2009-10-06
DE60313657T2 (de) 2008-01-03
EP1567133A2 (de) 2005-08-31
EP1567133B1 (de) 2007-05-02
AU2003291457A1 (en) 2004-06-03
JP2006508134A (ja) 2006-03-09
AU2003291457A8 (en) 2004-06-03
WO2004043433A2 (en) 2004-05-27
CA2505130A1 (en) 2004-05-27
DE60313657D1 (de) 2007-06-14
WO2004043433A3 (en) 2004-12-29
US20050287177A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
TW366346B (en) 1,3-oxathiolane nucleoside analogue
EA199700203A1 (ru) Синергические комбинации зидовудина, 1592u89 и 3тс или ftc
PL398295A1 (pl) Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
AU2003291726A8 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
UY26615A1 (es) Inhibidor de la glucogeno fosforilasa.
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
EP1720556A4 (de) Neue 2'-c-methyl-nucleosid-derivate
DE60313657D1 (de) Antivirale zusammensetzungen
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
UY24930A1 (es) Composiciones farmaceuticas que contienen (2r, cis)-4-amino-1-(2-hidroximetil-1,3 -oxatiolan-5-il)-(1h)-pirimidin-2-ona (lamivudina)
YU58398A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv
NO20065791L (no) Asyklovir-formuleringer
MEP34308A (en) Oral formulations of cladribine
BRPI0313645A2 (pt) composições de inalação com relações de droga elevadas.
JP2006508134A5 (de)
AR040242A1 (es) Composiciones farmaceuticas
BRPI0417513A (pt) agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas
AR026255A1 (es) Combinaciones antivirales.
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
ECSP982450A (es) Composiciones farmaceuticas
ATE393768T1 (de) Nukleosidanaloga mit antiviraler wirkung
RU2005138167A (ru) Противовирусное средство (варианты) и способ лечения на его основе

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties